XPH:NYE-SPDR® S&P Pharmaceuticals ETF (USD)

ETF | Health |

Last Closing

USD 41.21

Change

+0.12 (+0.29)%

Market Cap

N/A

Volume

0.04M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-30 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.19 (+0.85%)

USD 35.08B
FHLC Fidelity® MSCI Health Care In..

+0.46 (+0.70%)

USD 2.50B
FXH First Trust Health Care AlphaD..

+0.56 (+0.56%)

USD 0.89B
XHE SPDR® S&P Health Care Equipme..

-0.93 (-1.17%)

USD 0.16B
IDNA iShares Genomics Immunology an..

+0.28 (+1.35%)

USD 0.10B
XHS SPDR® S&P Health Care Service..

-0.36 (-0.37%)

USD 0.09B
SBIO ALPS Medical Breakthroughs ETF

+0.48 (+1.64%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

-0.03 (-0.11%)

USD 0.04B
BBP Virtus LifeSci Biotech Product..

+0.97 (+1.67%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.40 (+2.14%)

USD 0.01B

ETFs Containing XPH

INAV 10.31 % 0.00 %

N/A

N/A
MSSS Northern Lights Fund Trus.. 9.69 % 0.00 %

N/A

USD 0.08B

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.14% 38% F 44% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.14% 38% F 42% F
Trailing 12 Months  
Capital Gain 2.18% 71% C- 51% F
Dividend Return 1.25% 94% A 25% F
Total Return 3.44% 71% C- 42% F
Trailing 5 Years  
Capital Gain 1.23% 33% F 34% F
Dividend Return 6.13% 68% D+ 12% F
Total Return 7.36% 33% F 23% F
Average Annual (5 Year Horizon)  
Capital Gain -3.62% 33% F 19% F
Dividend Return -2.81% 33% F 13% F
Total Return 0.81% 68% D+ 19% F
Risk Return Profile  
Volatility (Standard Deviation) 13.14% 71% C- 70% C-
Risk Adjusted Return -21.41% 19% F 12% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.